Vernon, John; Goldberg, Robert; Golec, Joseph - In: PharmacoEconomics 27 (2009) 10, pp. 797-806
In this article we describe how reimbursement cost-effectiveness thresholds, per unit of health benefit, whether set explicitly or observed implicitly via historical reimbursement decisions, serve as a signal to firms about the commercial viability of their R&D projects (including candidate...